21
views
0
recommends
+1 Recommend
1 collections
    0
    shares

      Call for Papers: Sex and Gender in Neurodegenerative Diseases

      Submit here before September 30, 2024

      About Neurodegenerative Diseases: 3.0 Impact Factor I 4.3 CiteScore I 0.695 Scimago Journal & Country Rank (SJR)

      • Record: found
      • Abstract: found
      • Article: found

      Socioeconomic Status and Long-Term Stroke Mortality, Recurrence and Disability in Iran: The Mashhad Stroke Incidence Study

      research-article

      Read this article at

      ScienceOpenPublisherPubMed
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Background: Little is known about the association between socioeconomic status and long-term stroke outcomes, particularly in low- and middle-income countries. Methods: Patients were recruited from the Mashhad Stroke Incidence Study in Iran. We identified different socioeconomic variables including the level of education, occupation, household size, and family income. Residential location according to patient’s neighbourhood was classified into less privileged area (LPA), middle privileged area and high privileged area (HPA). Using Cox regression, competing risk analysis and logistic regression models, we determined the association between socioeconomic status and 1- and 5-year stroke outcomes. Generalized linear model was used for adjusting associated variables for stroke severity. Results: Six hundred twenty-four patients with first-ever stroke were recruited in this study. Unemployment prior to stroke was associated with an increased risk of 1- and 5-year post-stroke mortality (1 year: adjusted hazard ratio [aHR] 3.3; 95% CI 1.6–7.06: p = 0.001; 5 years: aHR 2.1; 95% CI 1.2–3.6: p = 0.007). The 5-year mortality rate was higher in less educated patients (<12 years) as compared to those with at least 12 years of schooling (aHR 1.84; 95% CI 1.05–3.23: p = 0.03). Patients living in LPA compared to those living in HPAs experienced a more severe stroke at admission (aB 3.84; 95% CI 0.97–6.71, p = 0.009) and disabling stroke at 1 year follow-up (OR 6.1; 95% CI 1.3–28.4; p = 0.02). Conclusion: A comprehensive stroke strategy should also address socioeconomic disadvantages.

          Related collections

          Author and article information

          Journal
          NED
          Neuroepidemiology
          10.1159/issn.0251-5350
          Neuroepidemiology
          S. Karger AG
          0251-5350
          1423-0208
          2019
          August 2019
          16 April 2019
          : 53
          : 1-2
          : 27-31
          Affiliations
          [_a] aClinical Research Unit, Mashhad University of Medical Sciences, Mashhad, Iran
          [_b] bStroke and Ageing Research, Department of Medicine, School of Clinical Sciences at Monash Health, Monash University, Clayton, Victoria, Australia
          [_c] cDepartment of Epidemiology and Biostatistics, Schulich School of Medicine and Dentistry, Western University, London, Ontario, Canada
          [_d] dDepartment of Family Medicine, Schulich School of Medicine and Dentistry, Western University, London, Ontario, Canada
          [_e] eDepartment of Population Health, Luxembourg Institute of Health, Strassen, Luxembourg
          [_f] fDepartment of Medicine and Institute of Health Policy, Management and Evaluation, University of Toronto, Toronto, Ontario, Canada
          [_g] gDepartment of Neurology, Lozano-Long School of Medicine, University of Texas Health, Tyler, Texas, USA
          [_h] hDepartment of Neurology, Mashhad University of Medical Sciences, Mashhad, Iran
          [_i] iDepartment of Neurology, North Khorasan University of Medical Sciences, Bojnord, Iran
          [_j] jDepartment of Psychiatry and Behavioral Neurosciences, Western University, London, Ontario, Canada
          [_k] kDepartment of Psychiatry, Mashhad University of Medical Sciences, Mashhad, Iran
          [_l] lStroke Prevention and Atherosclerosis Research Centre, Robarts Research Institute, Western University, London, Ontario, Canada
          [_m] mDepartment of Clinical Neurological Sciences, Western University, London, Ontario, Canada
          Author notes
          *Dr. Mahmoud Reza Azarpazhooh, Department of Clinical Neurological Sciences, University Hospital, 339 Windermere Road, London, ON N6A 5A5 (Canada), E-Mail reza.azarpazhooh@lhsc.on.ca
          Article
          494885 Neuroepidemiology 2019;53:27–31
          10.1159/000494885
          30991387
          c0b95cdc-2166-48f7-b3ea-5a00efc3d2dc
          © 2019 S. Karger AG, Basel

          Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher. Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug. Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

          History
          : 08 July 2018
          : 25 October 2018
          Page count
          Figures: 1, Pages: 5
          Categories
          Original Paper

          Geriatric medicine,Neurology,Cardiovascular Medicine,Neurosciences,Clinical Psychology & Psychiatry,Public health
          Recurrence,Socioeconomic,Population-based studies,Stroke,Mortality,Disability

          Comments

          Comment on this article